<?xml version="1.0" encoding="UTF-8"?>
<p>A case report from South-Korea described the use of LPV/r in a COVID-19 patient with mild respiratory symptoms.
 <sup>
  <xref rid="bibr26-2048872620922790" ref-type="bibr">26</xref>
 </sup> LPV/r was started at day 10 of illness. No clear inhibitory effect on viral RNA was observed in the daily sputum samples. In a randomised, controlled, open-label trial involving hospitalised adult patients with severe COVID-19, 99 patients were treated with LPV/r, while 100 patients received the standard care treatment.
 <sup>
  <xref rid="bibr27-2048872620922790" ref-type="bibr">27</xref>
 </sup> No difference in the time to clinical improvement and in mortality was observed between both groups.
</p>
